welcome to the businessroundups.org Exchange, a weekly newsletter for startups and markets. It is inspired by the daily businessroundups.org+ column from which it takes its name. Do you want it in your inbox every Saturday? Register here.
It’s always nice to start a new year with a dose of optimism – as long as it’s warranted. After reviewing PitchBook’s latest analysis, I’m starting to rethink my expectations for closing germ-stage deals in 2023, and maybe you will too. at. Let’s investigate. — Anna
As 2022 came to a close, I tried to keep my expectations in check: If even Instacart wasn’t ready to go public, I had to prepare for the lack of tech IPOs to continue in the first quarter or even the first half of 2023.
But early stage venture capital activity was one of the things I was fairly optimistic about going into the new year. Sure, public market woes had trickled down to private deals. But while the number of post-Series A deals and deal volume were impacted, investment activity in the angel and seed stage seemed quite stable.